Skip to main content
Passa alla visualizzazione normale.

SERGIO SIRAGUSA

Buffy coat-derived platelets cryopreserved using a new method: Results from in vitro studies

  • Authors: Napolitano, Mariasanta*; Mancuso, Salvatrice; Lo Coco, Lucio; Arfò, Piera Stefania; Raso, Simona; De Francisci, Giovanni; Dieli, Francesco; Caccamo, Nadia; Reina, Amalia; Dolce, Alberto; Agliastro, Rosalia; Siragusa, Sergio
  • Publication year: 2018
  • Type: Articolo in rivista (Articolo in rivista)
  • Key words: Cryopreserved platelets; DMSO; In vitro study; Viability; Hematology
  • OA Link: http://hdl.handle.net/10447/305592

Abstract

Cryopreservation for the long-term storage of platelets (PLTs) is a useful method to overcome the limits of platelet shortage. This is an in vitro prospective study to evaluate the count, viability, and function of buffy coat-derived pooled platelet concentrates (BC-PLTs), treated with dimethyl sulphoxide (DMSO) and cryopreserved (CRY BC-PLTs) at −80 °C with a modified Valeri method. PLTs were stored in 6% DMSO with a patented kit. Overall, 49 BC-PLTs from 245 healthy volunteer donors were prepared, cryopreserved, and analysed before and after 3, 6, and 9 months of storage. In flow cytometry, a statistically significant reduction in CD 42b (92.7 ± 4.29% at T0 vs. 23.6 ± 27.5% at T3, 16.38 ± 12.54% at T6, and 17.3 ± 9.6% at T9) and PAC-1 (1.9 ± 1.34% at T0 vs. 0.62 ± 0.4% at T3, 0.63 ± 0.83% at T6, and 0.49 ± 0.48% at T9) was observed after storage. CRY BC-PLTs showed a good and stable endogenous thrombin generation potential (nM min): 529.25 ± 98.64 at T0 vs. 533.04 ± 103.15 at T9 months. CRY BC-PLTs showed a good viability in vitro, according to currently accepted criteria for cryopreserved PLTs.